NCT05918302 2026-03-06
LEVEL
Grupo Espanol de Tumores Neuroendocrinos
Phase 3 Recruiting
Clinical Trials
17 trialsNCT02811861 2026-02-23
CLEAR
Eisai Inc.
Phase 3 Active not recruiting
NCT07405164 2026-02-12
MK-6482-043
Merck Sharp & Dohme LLC
Phase 3 Not yet recruiting
NCT07407517 2026-02-12
POLARIS
Fudan University
Phase 3 Not yet recruiting
NCT01674140 2026-02-10
e3
SWOG Cancer Research Network
Phase 3 Active not recruiting
NCT05476939 2026-02-05
BIOMEDE 2
Gustave Roussy, Cancer Campus, Grand Paris
Phase 3 Recruiting
NCT02962414 2026-02-03
Roll-over Study to Collect and Assess Long-term Safety of Everolimus in Patients With TSC and Refractory Seizures Who Have Completed the EXIST-3 Study [CRAD001M2304] and Who Are Benefitting From Continued Treatment
Novartis
Phase 3 Active not recruiting
NCT05306340 2026-01-30
A Study Evaluating the Efficacy and Safety of Giredestrant Plus Everolimus Compared With the Physician's Choice of Endocrine Therapy Plus Everolimus in Participants With Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer (evERA Breast Cancer)
Genentech, Inc.
Phase 3 Active not recruiting
NCT05477576 2026-01-20
ACTION-1
RayzeBio, Inc.
Phase 3 Recruiting
NCT00799188 2025-12-19
CERTICOEUR
Hospices Civils de Lyon
Phase 3 Completed
NCT06680921 2025-09-22
A Study of SIM0270 Combined With Everolimus vs. Treatment of Physician's Choice in Patients With ER+/HER2- Advanced Breast Cancer (SIMRISE)
Jiangsu Simcere Pharmaceutical Co., Ltd.
Phase 3 Recruiting
NCT01120249 2025-09-16
S0931
SWOG Cancer Research Network
Phase 3 Completed
NCT04919226 2025-09-10
COMPOSE
ITM Solucin GmbH
Phase 3 Active not recruiting
NCT03049189 2025-05-30
COMPETE
ITM Solucin GmbH
Phase 3 Active not recruiting
NCT01805271 2025-05-14
Safety Study of Adding Everolimus to Adjuvant Hormone Therapy in Women With High Risk of Relapse, ER+ and HER2- Primary Breast Cancer, Free of Disease After Receiving at Least One Year of Adjuvant Hormone Therapy
UNICANCER
Phase 3 Active not recruiting
NCT02246127 2025-05-11
SEQTOR
Grupo Espanol de Tumores Neuroendocrinos
Phase 3 Completed
NCT04195750 2025-04-29
A Study of Belzutifan (MK-6482) Versus Everolimus in Participants With Advanced Renal Cell Carcinoma (MK-6482-005)
Merck Sharp & Dohme LLC
Phase 3 Active not recruiting